nach oben

Erschienen in:

01.02.2009 | Original Article

Clinical Characteristics of Patients with Hepatitis C Virus-Related Chronic Liver Disease Seropositive for Anticentromere Antibody

verfasst von: Takashi Himoto, Seiji Nakai, Fumihiko Kinekawa, Hirohito Yoneyama, Akihiro Deguchi, Kazutaka Kurokochi, Tsutomu Masaki, Shoichi Senda, Reiji Haba, Seishiro Watanabe, Mikio Nishioka, Shigeki Kuriyama

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

The association between anticentromere antibody (ACA) and hepatitis C virus (HCV) infection remains unclear. We subjected eight patients with HCV-related chronic liver disease (CLD) seropositive for ACA to a battery of clinical and laboratory tests. The patient cohort was dominated by females, and four of the eight (50%) patients had a concomitant autoimmune disease. All of the patients had high titers of ACA (≥1:320). The histological activity index scores in chronic hepatitis C (CH-C) patients with ACA were significantly higher than those in CH-C patients without antinuclear antibody (ANA) (12.8 ± 1.8 vs. 8.3 ± 4.5, P = 0.0372). The frequency of human leukocyte antigen (HLA) DR-8 in patients with HCV-related CLD seropositive for ACA was significantly higher than that in patients with CH-C seronegative for ANA (71 vs. 18%, P = 0.0108). These findings suggest that ACA is induced by chronic HCV infection in association with HLA DR-8, and that CH-C patients with ACA exhibit more severe hepatic fibrosis and inflammation than CH-C patients without ANA.

Moroi Y, Peebles C, Flitzler MJ, Steigerwald J, Tan EM (1980) Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 77:1627–1631PubMedCrossRef

Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum 23:617–625PubMedCrossRef

Fritzler MJ, Kinsella TD (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526PubMedCrossRef

Earnshaw W, Bordwell B, Marino C, Rothfield N (1986) Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies. J Clin Invest 77:426–430PubMedCrossRef

Earnshaw WC, Sullivan KF, Machlin PS, Cooke CA, Kaiser DA et al (1987) Molecular cloning of cDMA for CENP-B, the major human centromere autoantigen. J Cell Biol 104:817–829PubMedCrossRef

Berstein RM, Callender ME, Neuberger JM, Hughes GRV, Williams R (1982) Anticentromere antibody in primary biliary cirrhosis. Am Rheum Dis 41:612–614CrossRef

Makinenn D, Fritzler M, Davis P, Sherlock S (1983) Anticentromere antibody in primary biliary cirrhosis. Arthritis Rheum 26:914–917CrossRef

Czaja AJ, Nishioka M, Morshed SA, Hachiya T (1994) Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 107:200–207PubMed

Shoji I, Takagi T, Kasukawa R (1992) Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern Med 31:1348–1355PubMedCrossRef

10.

Yoshida N, Sumino Y, Ueno Y, Shibata M, Sadamoto T, Sato G et al (1989) Clinical significance of anticentromere antibody in primary biliary cirrhosis. Acta Hepatol Jpn 30:1578–1583

11.

Tojo J, Ohira H, Suzuki T, Takeda I, Shoji I et al (2002) Clinicolaboratory characteristics of patients with primary billiary cirrhosis associated with CREST syndrome. Hepatol Res 22:187–195PubMedCrossRef

12.

Rigamonti C, Shand LM, Feudjo M, Bunn CC, Black CM, Denton CP et al (2006) Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 55:388–394PubMedCrossRef

13.

Imai H, Kiyosawa K, Yamaguchi K, Furuta S, Okumura N, Kumagai T et al (1987) The clinical significance of anticentromere antibodies (ACA) in sera of patients with autoimmune liver disease. Acta Hepatol Jpn 28:1164–1171

14.

Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA (1993) Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 18:342–352PubMedCrossRef

15.

Fried MW, Draguesku JO, Shindo M, Simpson LH, Banks SM, Hoofnagle JH et al (1993) Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci 38:631–636PubMedCrossRef

16.

Abuaf N, Lunel F, Giral P, Borotto E, Laperche S, Poupon R et al (1993) Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol 18:359–364PubMedCrossRef

17.

Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M et al (1995) High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 21:613–619PubMed

18.

Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R et al (1997) Serum antoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 26:561–566PubMedCrossRef

19.

Nishioka M, Morshed SM, Kono K, Himoto T, Parveen S, Arima K et al (1997) Frequency and significance of antibodies to p450 IID6 protein in Japanese patients with chronic hepatitis C. J Hepatol 26:992–1000PubMedCrossRef

20.

Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L et al (1999) Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 45:435–441PubMedCrossRef

21.

Peng YC, Hsieh SC, Yang DY, Tung CF, Hu WH, Huang WN, Chen GH (2001) Expression and clinical significance of antinuclear antibody in hepatitis C virus infection. J Clin Gastroenterol 33:402–406PubMedCrossRef

22.

Yee LJ, Goldin KRD, Marshall S, Thomas HC, Alberti A, Chiaramonte M et al (2004) Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Vir Hepat 11:459–464CrossRef

23.

Muratori P, Muratori L, Guidi M, Granito A, Susca M, Lenzi M, Bianchi FB (2005) Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 40:501–507PubMedCrossRef

24.

Hsieh MY, Dai CY, Lee LP, Huang JF, Tsai WC, Hou NJ et al (2008) The antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in chronic hepatitis C patients. J Clin Pathol 61:333–337

25.

Pawlotsky JM, Yahia MB, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F et al (1994) Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 19:841–848PubMed

26.

Manns MP, Rambusch EG (1999) Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 31[Suppl1]:39–42

27.

Sherman KE, O’Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P et al (1993) Quantitative evaluation of hepatitis C virus in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 31:2679–2682PubMed

28.

Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS et al (1993) Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501–1504PubMedCrossRef

29.

Simmonds P, Alberti A, Alter HJ, Bomino F, Bradley DW, Brechot C et al (1994) A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321–1324PubMed

30.

Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T et al (1996) New Inuyama classification: new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 6:112–119CrossRef

31.

Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N et al (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435PubMedCrossRef

32.

Bach N, Thung SN, Schaffner F (1992) The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 15:572–577PubMedCrossRef

33.

Scheuer PJ, Ashrafzadeh P, Sherlock S, Bromn D, Dusheiko GM (1992) The pathology of hepatitis C. Hepatology 15:567–571PubMedCrossRef

34.

Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC et al (1993) Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis C. Gastroenterology 104:595–603PubMed

35.

Goodman ZD, Ishak KG (1995) Histopathology of hepatitis C virus infection. Sem Liver Dis 15:70–81CrossRef

36.

Czaja A, Carpenter HA (1997) Histological findings in chronic hepatitis C with autoimmune features. Hepatology 26:459–466PubMedCrossRef

37.

Freni MA, Artuso D, Gerken G, Spanti C, Marafioti T, Alessi N et al (1995) Focal lymphocytic aggregates in chronic hepatitis C: occurrence, immunohistochemical characterization, and relation to markers of autoimmunity. Hepatology 22:389–394PubMed

38.

Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughts AK, Cancado EL et al (1999) International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938PubMedCrossRef

39.

Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y (1978) Microdroplet testing for HLA-A, -B, -C and -D antigens. Am J Clin Pathol 69:103–120PubMed

40.

Bonaci-Nikolic B, Andrejevic S, Bukilica M, Urosevic I, Nikolic M (2006) Autoantibodies to mitotic apparatus: association with other autoantibodies and their clinical significance. J Clin Immunol 26:438–446PubMedCrossRef

41.

Ramos-Casals M, Pares A, Jara LJ, Solans R, Ninas O, Vazquez P et al (2005) Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. J Viral Hepat 12:648–654PubMedCrossRef

42.

Riveille JD, Solomon DH (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl–70, and nucleolar antibodies. Arthritis Rheum 49:399–412CrossRef

43.

Gordon MB, Klein I, Dekker A, Rodnan G, Medsger TA (1981) Thyroid disease in progressive systemic sclerosis: increased frequency of glandular fibrosis and hypothyroidism. Ann Intern Med 95:431–435PubMed

44.

Caramaschi P, Biasi D, Manzo T, Carletto A, Poli F, Bambara LM (1995) Anticentromere antibody-clinical associations a study of 44 patients. Rheumatol Int 14:253–255PubMedCrossRef

45.

Katano K, Kawano M, Koni I, Sugai S, Muro Y (2001) Clinical and laboratory features of anticentromere antibody positive primary Sjögren’s syndrome. J Rheumatol 28:2238–2244PubMed

46.

Hashimoto M, Kinoshita T, Yamasaki M, Tanaka H, Imanishi T, Ihara H et al (1994) Gene frequencies and haplotypic associations within the HLA region in 916 unrelated Japanese individuals. Tissue Antigens 44:166–173PubMedCrossRef

47.

Miyamori H, Kato Y, Kobayashi K, Hattori N (1983) HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis. Digestion 26:213–217PubMed

48.

Maeda T, Onishi S, Saibara T, Iwasaki S, Yamamoto Y (1992) HLA DRw8 and primary biliary cirrhosis. Gastroenterology 103:118–119

49.

Genth E, Mierau R, Genetzky P, von Muhlen CA, Kaufmann S, von Wilmowsky H et al (1990) Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 33:657–665PubMedCrossRef

50.

Kuwana M, Okano Y, Kaburaki J, Inoko H (1995) HLA class II genes associated with anticentromere antibody in Japanese patients with systemic scleroisis (scleroderma). Ann Rheum Dis 54:983–987PubMedCrossRef

51.

Onami K, Moteki S, Yoshida H, Kasukawa R (1993) Human leukocyte antigen (HLA) in cases of CREST syndrome and PBC-CREST overlap syndrome reported in Japan. Jpn J Clin Immun 16:208–215

52.

Pan SF, Rodnan GP, Wald N (1971) Chromosonal abnormalities in progressive systemic sclerosis (scleroderma). Arthritis Rheum 14:407–408

53.

Aoki A, Kirino Y, Ishigatsubo Y, Senuma A, Nagaoka S (2004) Liver involvement in primary Sjögren’s syndrome. Jpn J Clin Immunol 27:397–401CrossRef

54.

Muro Y, Azuma N, Onouchi H, Kunimatsu M, Tomita Y, Sasaki M et al (2000) Autoepitopes on autoantigen centromere protein-A (CENP-A) are restricted to the N-terminal region, which has no homology with histone H3. Clin Exp Immunol 120:218–223PubMedCrossRef

55.

Russo K, Hoch S, Dima C, Varga J, Teodorescu M (2000) Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 27:142–147PubMed

56.

Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M et al (2007) Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45:118–127PubMedCrossRef

57.

Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB (2004) Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2:1116–1122PubMedCrossRef

58.

Higuchi M, Horiuchi T, Ishibashi N, Yoshizawa S, Niho Y, Nagasawa K (2000) Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 19:123–126PubMedCrossRef

59.

Conrad K (2000) Autoantibodies in cancer patients and in persons with a higher risk of cancer development. In: Shoenfeld Y, Gershwin MF (eds) Cancer and autoimmunity. Elsevier, Amsterdam, pp 159–174CrossRef

Titel: Clinical Characteristics of Patients with Hepatitis C Virus-Related Chronic Liver Disease Seropositive for Anticentromere Antibody
verfasst von: Takashi Himoto
Seiji Nakai
Fumihiko Kinekawa
Hirohito Yoneyama
Akihiro Deguchi
Kazutaka Kurokochi
Tsutomu Masaki
Shoichi Senda
Reiji Haba
Seishiro Watanabe
Mikio Nishioka
Shigeki Kuriyama
Publikationsdatum: 01.02.2009
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 2/2009
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0359-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Study of the Association Between Polymorphisms of the COL1A1 Gene and HBV-Related Liver Cirrhosis in Chinese Patients

Additive Inhibitory Effect of Experimentally Induced Hepatic Cirrhosis by Agonists of Peroxisome Proliferator Activator Receptor γ and Retinoic Acid Receptor

Gastrointestinal Manifestations of Behçet’s Disease

Successful Rescue Therapy with Only 4 Weeks Ribavirin Monotherapy in End-Stage Cirrhosis Due to Genotype 2 Chronic Hepatitis C

Effect of Sildenafil in an Experimental Model of Ischemic Colitis

Liberal Policy in Living Donor Liver Transplantation for Hepatocellular Carcinoma: Lessons Learned